title: Reduction of ischemic brain injury by topical application of insulin-like growth factor-I after transient middle cerebral artery occlusion in rats.
abstract: In order to examine the effect of insulin-like growth factor-1 (IGF-1) on ischemic brain injury, IGF-1 was applied topically on the surface of reperfused rat brain after 60 min of transient middle cerebral artery occlusion (MCAO). In contrast to the cases treated with vehicle, the infarct area was greatly reduced at 24 h of reperfusion by treatment with IGF-1. Terminal deoxynucleotidyl transferase mediated dUTP-biotin in situ nick labeling (TUNEL) staining and immunoreactivity for glycogen synthase kinase 3beta (GSK3beta) were also markedly reduced in the brains with IGF-1 treatment. The present results suggest that the treatment with IGF-1 significantly ameliorates brain injury after transient focal brain ischemia associated with the reduction of TUNEL and GSK3beta stainings.
authors.affiliation: Department of Neurology, Okayama University Medical School, 2-5-1 Shikatacho, Okayama, Japan.
authors.forename: J M
authors.initials: JM
authors.lastname: Wang
authors.forename: T
authors.initials: T
authors.lastname: Hayashi
authors.forename: W R
authors.initials: WR
authors.lastname: Zhang
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: Y
authors.initials: Y
authors.lastname: Shiro
authors.forename: K
authors.initials: K
authors.lastname: Abe
mesh_terms: D000287:Administration, Topical; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D001921:Brain / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology*; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D038362:Glycogen Synthase Kinase 3; D038341:Glycogen Synthase Kinases; D020287:In Situ Nick-End Labeling; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D020768:Middle Cerebral Artery / Q000473:pathology* / Q000503:physiopathology* / Q000601:surgery; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D007334:Insulin-Like Growth Factor I; D038341:Glycogen Synthase Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D038362:Glycogen Synthase Kinase 3